Skip to main content
NCBI home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1997 Sep;4(5):583–586. doi: 10.1128/cdli.4.5.583-586.1997

Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis.

R C Smallridge 1, G C Tsokos 1, K D Burman 1, L Porter 1, T Cranston 1, P P Sfikakis 1, B L Solomon 1
PMCID: PMC170601  PMID: 9302209

Abstract

Thyrotoxic patients exhibit increased levels of immune activation molecules (soluble interleukin-2 receptor [sIL-2R], intercellular adhesion molecule-1 [ICAM-1], and endothelial-leukocyte adhesion molecule-1 [ELAM-1]) in serum, although the clinical significance of these measurements remains unclear. In a randomized 4-week study, we have recently shown that in the treatment of hyperthyroidism, the combination of cholestyramine and methimazole (MMI) resulted in faster lowering of serum thyroid-hormone levels than did MMI alone. Stored serial serum samples from patients participating in this randomized treatment trial were analyzed for sIL-2R, soluble ICAM-1 (sICAM-1), and soluble ELAM-1 (sELAM-1). The levels of all three molecules were elevated in patients with hyperthyroidism. Although the levels of sICAM-1 and sELAM-1 remained elevated through the 4-week follow-up period in both groups of patients, the sIL-2R levels (normal levels, 1.0 to 4.2 ng/ml) decreased significantly in the 10 patients who received cholestyramine in addition to MMI (week 0, 14.2 +/- 1.5 ng/ml; week 2, 10.8 +/- 1.2 ng/ml; week 4, 8.9 +/- 1.5 ng/ml). In eight patients who received MMI alone, sIL-2R decreased less rapidly (week 0, 12.3 +/- 1.4 ng/ml; week 2, 12.3 +/- 1.3 ng/ml; week 4, 10.9 +/- 1.3 ng/ml). sICAM-1 and sELAM-1 were elevated at baseline but did not decrease during therapy. In the former group, free thyroxine and free triiodothyronine decreased faster. These data show that levels of sIL-2R in serum, but not those of sICAM-1 and sELAM-1, may be of clinical use in the early follow-up evaluation of medically treated patients.

Full Text

The Full Text of this article is available as a PDF (182.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Campen D. H., Horwitz D. A., Quismorio F. P., Jr, Ehresmann G. R., Martin W. J. Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum. 1988 Nov;31(11):1358–1364. doi: 10.1002/art.1780311103. [DOI] [PubMed] [Google Scholar]
  2. Chow C. C., Lai K. N., Leung J. C., Chan J. C., Cockram C. S. Serum soluble interleukin 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy. Clin Endocrinol (Oxf) 1990 Sep;33(3):317–321. doi: 10.1111/j.1365-2265.1990.tb00496.x. [DOI] [PubMed] [Google Scholar]
  3. De Bellis A., Bizzarro A., Gattoni A., Romano C., Di Martino S., Sinisi A. A., Abbadessa S., Bellastella A. Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma. J Clin Endocrinol Metab. 1995 Jul;80(7):2118–2121. doi: 10.1210/jcem.80.7.7541801. [DOI] [PubMed] [Google Scholar]
  4. Escobar-Morreale H. F., Serrano-Gotarredona J., Villar L. M., García-Robles R., González-Porqué P., Sancho J. M., Varela C. Methimazole has no dose-related effect on the serum concentrations of soluble class I major histocompatibility complex antigens, soluble interleukin-2 receptor, and beta 2-microglobulin in patients with Graves' disease. Thyroid. 1996 Feb;6(1):29–36. doi: 10.1089/thy.1996.6.29. [DOI] [PubMed] [Google Scholar]
  5. Koukkou E., Panayiotidis P., Alevizou-Terzaki V., Thalassinos N. High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism. J Clin Endocrinol Metab. 1991 Oct;73(4):771–776. doi: 10.1210/jcem-73-4-771. [DOI] [PubMed] [Google Scholar]
  6. Lipnick R. N., Sfikakis P. P., Klipple G. L., Tsokos G. C. Elevated soluble CD8 antigen and soluble interleukin-2 receptors in the sera of patients with juvenile rheumatoid arthritis. Clin Immunol Immunopathol. 1993 Jul;68(1):64–67. doi: 10.1006/clin.1993.1096. [DOI] [PubMed] [Google Scholar]
  7. Mariotti S., Caturegli P., Barbesino G., Del Prete G. F., Chiovato L., Pinchera A. Circulating soluble interleukin 2 receptor concentration is increased in both immunogenic and nonimmunogenic hyperthyroidism. J Endocrinol Invest. 1991 Oct;14(9):777–781. doi: 10.1007/BF03347915. [DOI] [PubMed] [Google Scholar]
  8. Mariotti S., Caturegli P., Barbesino G., Marinò M., Del Prete G. F., Chiovato L., Tonacchera M., De Carli M., Pinchera A. Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseases. Clin Endocrinol (Oxf) 1992 Nov;37(5):415–422. doi: 10.1111/j.1365-2265.1992.tb02352.x. [DOI] [PubMed] [Google Scholar]
  9. Nakanishi K., Taniguchi Y., Ohta Y. Increased soluble interleukin 2 receptor levels in autoimmune thyroid disease. Acta Endocrinol (Copenh) 1991 Sep;125(3):253–258. doi: 10.1530/acta.0.1250253. [DOI] [PubMed] [Google Scholar]
  10. Rubin L. A., Nelson D. L. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990 Oct 15;113(8):619–627. doi: 10.7326/0003-4819-113-8-619. [DOI] [PubMed] [Google Scholar]
  11. Sfikakis P. P., Charalambopoulos D., Vayiopoulos G., Oglesby R., Sfikakis P., Tsokos G. C. Increased levels of intercellular adhesion molecule-1 in the serum of patients with systemic lupus erythematosus. Clin Exp Rheumatol. 1994 Jan-Feb;12(1):5–9. [PubMed] [Google Scholar]
  12. Sfikakis P. P., Tesar J., Baraf H., Lipnick R., Klipple G., Tsokos G. C. Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Immunol Immunopathol. 1993 Jul;68(1):88–92. doi: 10.1006/clin.1993.1100. [DOI] [PubMed] [Google Scholar]
  13. Sfikakis P. P., Tsokos G. C. Lymphocyte adhesion molecules in autoimmune rheumatic diseases: basic issues and clinical expectations. Clin Exp Rheumatol. 1995 Nov-Dec;13(6):763–777. [PubMed] [Google Scholar]
  14. Solomon B. L., Wartofsky L., Burman K. D. Adjunctive cholestyramine therapy for thyrotoxicosis. Clin Endocrinol (Oxf) 1993 Jan;38(1):39–43. doi: 10.1111/j.1365-2265.1993.tb00970.x. [DOI] [PubMed] [Google Scholar]
  15. Wenisch C., Myskiw D., Gessl A., Graninger W. Circulating selectins, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in hyperthyroidism. J Clin Endocrinol Metab. 1995 Jul;80(7):2122–2126. doi: 10.1210/jcem.80.7.7541802. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES